Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
about
Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg dailyBCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.
P2860
Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Dasatinib for the treatment of ...... kaemia after imatinib failure.
@en
Dasatinib for the treatment of ...... kaemia after imatinib failure.
@nl
type
label
Dasatinib for the treatment of ...... kaemia after imatinib failure.
@en
Dasatinib for the treatment of ...... kaemia after imatinib failure.
@nl
prefLabel
Dasatinib for the treatment of ...... kaemia after imatinib failure.
@en
Dasatinib for the treatment of ...... kaemia after imatinib failure.
@nl
P2860
P1476
Dasatinib for the treatment of ...... kaemia after imatinib failure.
@en
P2860
P304
P356
10.1517/14656566.8.18.3257
P407
P577
2007-12-01T00:00:00Z